Conference Coverage

Stable and durable factor IX (FIX) levels over 4 years after etranacogene dezaparvovec gene therapy administration in a Phase 2b trial in patients with haemophilia B

Human liver biopsy analysis reveals lower RNA transcription may contribute to a decline in FVIII levels following AAV5-hFVIII-SQ gene therapy

Seven-year follow-up of valoctocogene roxaparvovec gene therapy for haemophilia A

Health-related Quality of Life in Adults With Hemophilia B After Gene Therapy With Fidanacogene Elaparvovec in the BENEGENE-2 Trial

Safety and efficacy of valoctocogene roxaparvovec in participants with active and prior FVIII inhibitors

A Novel Gene Editing Lexicon Strategy for the Haemophilia Community

A New Tool to Assist in Treatment Selection–The World Federation of Hemophilia (WFH) Shared Decision-making (SDM) Tool

Back To Top
Image

About

Supported through educational grants from BioMarin, CSL Behring, Pfizer Inc., Roche, and Spark Therapeutics

Essential SSL